A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MORPHEUS- CRC)
Sponsor: |
F. Hoffmann La Roche Ltd |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR8538 |
U.S. Govt. ID: |
NCT03555149 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to compare the effects, good or bad, of the cancer immunotherapy combination treatments (CIT) combinations versus standard treatment on you and your colorectal cancer to find out which is better.
This study is closed
Investigator
Yoanna Pumpalova, MD
Are you 18 years of age or older? |
Yes |
No |
Do you have Metastatic Colorectal Cancer (mCRC)? |
Yes |
No |
Did you have disease progression during or following two separate lines of treatment? |
Yes |
No |